• Citer

Copy number aberration analysis to predict response to neoadjuvant antiHER2 therapy: results from the NeoALTTO phase III clinical trial

par Venet, David ;Rediti, Mattia ;Maetens, Marion M. ;Fumagalli, Debora ;Brown, David Norman ;Majjaj, Samira ;Salgado, Roberto;Pusztai, Lajos;Harbeck, Nadia;El-Abed, Sarra;Wang, Yingbo;Saura, Cristina;Gomez, H.L.;Semiglazov, Vladimir Fedorovich;de Azambuja, Evandro ;Huober, J.;Nuciforo, Paolo Giovanni;Di Cosimo, Serena;Piccart-Gebhart, Martine ;Loi, Sherene ;Rothé, Françoise ;Sotiriou, Christos
Référence Clinical cancer research, 27, 20, page (5607-5618)
Publication Publié, 2021-10-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Copy number aberration analysis to predict response to neoadjuvant antiHER2 therapy: results from the NeoALTTO phase III clinical trial
Auteur:	Venet, David; Rediti, Mattia; Maetens, Marion M.; Fumagalli, Debora; Brown, David Norman; Majjaj, Samira; Salgado, Roberto; Pusztai, Lajos; Harbeck, Nadia; El-Abed, Sarra; Wang, Yingbo; Saura, Cristina; Gomez, H.L.; Semiglazov, Vladimir Fedorovich; de Azambuja, Evandro; Huober, J.; Nuciforo, Paolo Giovanni; Di Cosimo, Serena; Piccart-Gebhart, Martine; Loi, Sherene; Rothé, Françoise; Sotiriou, Christos
Informations sur la publication:	Clinical cancer research, 27, 20, page (5607-5618)
Statut de publication:	Publié, 2021-10-01
Sujet CREF:	Cancérologie
MeSH keywords:	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Breast Neoplasms -- drug therapy -- genetics
	DNA Copy Number Variations
	Female
	Humans
	Neoadjuvant Therapy
	Neoplasm Recurrence, Local
	Receptor, ErbB-2 -- genetics -- therapeutic use
	Trastuzumab -- therapeutic use
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1078-0432
	info:doi/10.1158/1078-0432.CCR-21-1317
	info:pii/1078-0432.CCR-21-1317
	info:scp/85117405703
	info:pmid/34321278